McMinn Rachel
SEC insider (Form 3/4/5 filer). CIK 0001606302. Chief Executive Officer at Neurogene Inc. (NGNE). 5 reported Form 4/5 transactions since Sep 2024; latest on Sep 22, 2026. Located in NEW YORK, NY.
Companies McMinn Rachel has filed insider reports for
- Neurogene Inc. (NGNE): Director, Officer, Chief Executive Officer
McMinn Rachel
CIK: 0001606302
Transaction Breakdown
Open Market Buys (P)1 (20.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)1 (20.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NGNE
Neurogene Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 22, 2026NGNE
Neurogene Inc.
ExerciseDirect756 shares at avg. $25.32$19K - Mar 26, 2026NGNE
Neurogene Inc.
SaleDirect3.4K shares at avg. $22.07$74K - Feb 20, 2026NGNE
Neurogene Inc.
AwardDirect25.9K shares- - Mar 26, 2025NGNE
Neurogene Inc.
AwardDirect23.9K shares- - Nov 22, 2024NGNE
Neurogene Inc.
PurchaseDirect47.5K shares at avg. $20.40$969K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 22, 2026 | NGNE Neurogene Inc. | Exercise | 756 | $25.32 | $19,142 | Direct |
| Mar 26, 2026 | NGNE Neurogene Inc. | Sale | 3,352 | $22.07 | $73,995 | Direct |
| Feb 20, 2026 | NGNE Neurogene Inc. | Award | 25,900 | - | $0 | Direct |
| Mar 26, 2025 | NGNE Neurogene Inc. | Award | 23,900 | - | - | Direct |
| Nov 22, 2024 | NGNE Neurogene Inc. | Purchase | 47,500 | $20.40 | $969,000 | Direct |
1-5 of 5 transactions